Ascletis Pharma Statistics
Total Valuation
Ascletis Pharma has a market cap or net worth of HKD 7.37 billion. The enterprise value is 5.30 billion.
Market Cap | 7.37B |
Enterprise Value | 5.30B |
Important Dates
The last earnings date was Friday, May 30, 2025.
Earnings Date | May 30, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Ascletis Pharma has 962.85 million shares outstanding. The number of shares has decreased by -6.75% in one year.
Current Share Class | 962.85M |
Shares Outstanding | 962.85M |
Shares Change (YoY) | -6.75% |
Shares Change (QoQ) | -2.92% |
Owned by Insiders (%) | 64.62% |
Owned by Institutions (%) | 1.07% |
Float | 131.01M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 5,394.86 |
PB Ratio | 3.52 |
P/TBV Ratio | 3.54 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -16.54 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -14.48 |
Financial Position
The company has a current ratio of 12.88, with a Debt / Equity ratio of 0.00.
Current Ratio | 12.88 |
Quick Ratio | 12.82 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | -0.02 |
Interest Coverage | -1,658.33 |
Financial Efficiency
Return on equity (ROE) is -13.97% and return on invested capital (ROIC) is -11.70%.
Return on Equity (ROE) | -13.97% |
Return on Assets (ROA) | -10.96% |
Return on Invested Capital (ROIC) | -11.70% |
Return on Capital Employed (ROCE) | -20.52% |
Revenue Per Employee | 5,911 |
Profits Per Employee | -1.39M |
Employee Count | 231 |
Asset Turnover | 0.00 |
Inventory Turnover | 0.10 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +571.05% in the last 52 weeks. The beta is 0.36, so Ascletis Pharma's price volatility has been lower than the market average.
Beta (5Y) | 0.36 |
52-Week Price Change | +571.05% |
50-Day Moving Average | 6.59 |
200-Day Moving Average | 3.80 |
Relative Strength Index (RSI) | 57.85 |
Average Volume (20 Days) | 5,682,699 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ascletis Pharma had revenue of HKD 1.37 million and -320.25 million in losses. Loss per share was -0.32.
Revenue | 1.37M |
Gross Profit | 782,167 |
Operating Income | -430.60M |
Pretax Income | -320.25M |
Net Income | -320.25M |
EBITDA | -415.51M |
EBIT | -430.60M |
Loss Per Share | -0.32 |
Balance Sheet
The company has 2.08 billion in cash and 8.12 million in debt, giving a net cash position of 2.07 billion or 2.15 per share.
Cash & Cash Equivalents | 2.08B |
Total Debt | 8.12M |
Net Cash | 2.07B |
Net Cash Per Share | 2.15 |
Equity (Book Value) | 2.09B |
Book Value Per Share | 2.15 |
Working Capital | 1.93B |
Cash Flow
In the last 12 months, operating cash flow was -363.50 million and capital expenditures -2.23 million, giving a free cash flow of -365.73 million.
Operating Cash Flow | -363.50M |
Capital Expenditures | -2.23M |
Free Cash Flow | -365.73M |
FCF Per Share | -0.38 |
Margins
Gross Margin | 57.29% |
Operating Margin | -31,538.04% |
Pretax Margin | -23,455.65% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Ascletis Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 6.75% |
Shareholder Yield | n/a |
Earnings Yield | -4.35% |
FCF Yield | -4.97% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Ascletis Pharma has an Altman Z-Score of 4.29.
Altman Z-Score | 4.29 |
Piotroski F-Score | n/a |